Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 11:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Hyperglycemia Clear all
Not listed Not applicable Interventional

Evaluation of Flash Continuous Glucose Monitoring to Reduce Hyperglycemia in People With T2 Diabetes

NCT04843527
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
FreeStyle Libre System, FreeStyle Libre System plus food app
Device
Lead sponsor
Abbott Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Boston, Massachusetts • Detroit, Michigan • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 25, 2026, 11:45 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Vitamin K to Slow Progression of Dyslipidemia and Diabetes Risk (Vita-K 'n' Kids Study II)

NCT02959762
View directory record Official record
Conditions
Obesity, Insulin Resistance, Obesity in Diabetes, Nutritional and Metabolic Diseases, Hyperlipidemia, Hyperglycemia, Cardiovascular Diseases
Interventions
Placebo-Control, Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d), High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
8 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Sep 25, 2026, 11:45 AM EDT
Completed Phase 4 Interventional Results available

A Clinical Trial to Prevent New Onset Diabetes After Transplantation

NCT01683331
View directory record Official record
Conditions
Prevention of New Onset Diabetes Among Kidney Transplant Patients
Interventions
Insulin treatment for hyperglycemia
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Sep 25, 2026, 11:45 AM EDT
Completed Phase 4 Interventional Results available

Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery

NCT02443402
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Sep 25, 2026, 11:45 AM EDT
Completed Phase 4 Interventional Results available

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

NCT02741687
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 25, 2026, 11:45 AM EDT
Terminated Phase 3 Interventional

Effects of Pulsed Intravenous (IV) Insulin on Brittle and Uncontrolled Diabetes

NCT01029444
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pulsatile Intravenous Insulin Therapy (Humulin, Humulog, Novolog )
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 25, 2026, 11:45 AM EDT
Completed Early Phase 1 Interventional

Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy

NCT01945099
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ePID closed loop system, hyaluronidase, Lispro-PH20
Device · Drug
Lead sponsor
Yale University
Other
Eligibility
12 Years to 40 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Sep 25, 2026, 11:45 AM EDT
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

Tau PET Imaging in the Northern Manhattan Study of Metabolism and Mind.

NCT03389100
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Pre-diabetes
Interventions
18F-MK6240 injection
Drug
Lead sponsor
Columbia University
Other
Eligibility
55 Years to 69 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Sep 25, 2026, 11:45 AM EDT
Completed Not applicable Interventional Results available

Dietary Glycemic Index, Brain Function and Food Intake in Patients With Type 1 Diabetes Mellitus

NCT02772783
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
high GI meal, low GI meal, euglycemic insulin clamp, primed-variable insulin infusion
Other · Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 25, 2026, 11:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises

NCT00753142
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Intralipid 20%, Glucose infusion
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 25, 2026, 11:45 AM EDT
Completed No phase listed Observational

Assessment of Markers of Stress in Acute Ischemic Stroke With Hyperglycemia

NCT03318679
View directory record Official record
Conditions
Ischemic Stroke, Hyperglycemia
Interventions
No intervention is planned.
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 100 Years
Enrollment
88 participants
Timeline
2017 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Sep 25, 2026, 11:45 AM EDT
Completed Phase 4 Interventional Results available

Transitioning Open Heart Surgery Patients From Insulin Infusions to Detemir

NCT00717288
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Detemir
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 2, 2011 · Synced Sep 25, 2026, 11:45 AM EDT
Completed Not applicable Interventional Results available

Intervening in Diabetes With Healthy Eating, Activity, and Linkages To Healthcare - The I-D-HEALTH Study

NCT01435603
View directory record Official record
Conditions
Diabetes Mellitus, Hyperglycemia, Obesity, Glucose Metabolism Disorders, Metabolic Diseases, Endocrine System Diseases, Overnutrition, Nutrition Disorders, Overweight, Body Weight, Signs and Symptoms
Interventions
Standard Lifestyle Advice, Advice Plus Lifestyle Intervention
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Sep 25, 2026, 11:45 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

NCT00900146
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canakinumab, Metformin, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 74 Years
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
18
States / cities
Phoenix, Arizona • La Jolla, California • Los Gatos, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2012 · Synced Sep 25, 2026, 11:45 AM EDT
Terminated No phase listed Observational

Study of Stress Hyperglycemia as an Indicator of Diabetes Mellitus

NCT02068989
View directory record Official record
Conditions
Stress Hyperglycemia, Diabetes Mellitus Type 2
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
New Haven, Connecticut • Norwalk, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 4, 2016 · Synced Sep 25, 2026, 11:45 AM EDT
Completed Phase 4 Interventional Results available

Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia

NCT01184014
View directory record Official record
Conditions
Hyperglycemia
Interventions
NPH insulin plus Complete Insulin Orders, Complete Insulin Orders
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Sep 25, 2026, 11:45 AM EDT
Completed Not applicable Interventional

Postpartum Glycemia in Women At Risk for Persistent Hyperglycemia

NCT04521712
View directory record Official record
Conditions
Gestational Diabetes
Interventions
2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 25, 2026, 11:45 AM EDT
Recruiting Phase 4 Interventional

International Care Bundle Evaluation in Cerebral Hemorrhage Research

NCT06429332
View directory record Official record
Conditions
Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage, Stroke, Cerebrovascular Disease
Interventions
Reversal of Oral anticoagulation within 30 minutes, Early intensive blood pressure lowering, Treatment of pyrexia, Hyperglycemia treatment, Do-not-resuscitate (DNR) or withdrawal of care, Referral to Intensive Care, Referral to Neurosurgery, Repeat brain imaging, Standard care
Other · Diagnostic Test
Lead sponsor
Region Skane
Other
Eligibility
18 Years and older
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 25, 2026, 11:45 AM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin

NCT00715624
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Basal Insulin, Metformin, Pen auto-injector
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 27, 2016 · Synced Sep 25, 2026, 11:45 AM EDT
Terminated Early Phase 1 Interventional

Glyburide vs Glucovance in the Treatment of GDM

NCT02726490
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Glyburide, Glucovance
Drug
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2020 · Synced Sep 25, 2026, 11:45 AM EDT
Completed Phase 1 Interventional

Evaluate HM-002-1005 in Subjects With Type 2 Diabetes Mellitus

NCT06498284
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
HM-002-1005
Drug
Lead sponsor
Hua Medicine Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Sep 25, 2026, 11:45 AM EDT
Recruiting Phase 2 Interventional

Low-Dose Pioglitazone in Patients With NASH (AIM 2)

NCT04501406
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Steatohepatitis
Interventions
Pioglitazone, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 75 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 25, 2026, 11:45 AM EDT
Completed Phase 4 Interventional

Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy

NCT01239004
View directory record Official record
Conditions
Dyslipidemia, Hyperlipidemia, Hyperglycemia
Interventions
Placebo, Colesevelam
Drug
Lead sponsor
Radiant Research
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Chicago, Illinois • Kansas City, Kansas • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Sep 25, 2026, 11:45 AM EDT
Recruiting Not applicable Interventional

Glucose Empowerment Through Monitoring and Social Support in Pregnancy

NCT07009704
View directory record Official record
Conditions
Pregnancy, Complications, Gestational Diabetes
Interventions
Mobile-based social support, Real-time continuous glucose monitoring
Behavioral
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 25, 2026, 11:45 AM EDT